Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
The present invention identifies a number of gene markers whose expression is altered in neurodegenerative diseases (ND). These markers can be used to diagnose or predict ND in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent ND development or progression.
1. A method of predicting whether a human subject is afflicted with Parkinson's disease (PD) comprising:
(a) obtaining an mRNA- or protein-containing peripheral blood sample from said subject;
(b) determining the expression level of ST13 mRNA or protein in said sample;
(c) comparing the expression level of ST13 mRNA or protein with the expression level of ST13 mRNA or protein in peripheral blood samples from individuals not afflicted with PD; and
(d) determining decreased expression of ST13 mRNA or protein in the sample from said subject relative to said samples from individuals not afflicted with PD, thereby predicting said subject is afflicted with PD.
2. The method of claim 1 , further comprising determining the expression level of one or more genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
3. The method of claim 1 , further comprising determining the expression level of at least two genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
4. The method of claim 1 , further comprising determining the expression level of at least three genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
5. The method of claim 1 , further comprising determining the expression level of at least four genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
6. The method of claim 1 , further comprising determining the expression level of at least five genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
7. The method of claim 1 , further comprising determining the expression level of at least six genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
8. The method of claim 1 , further comprising determining the expression level of at least seven genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
9. The method of claim 1 , further comprising determining the expression level of at least eight genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
10. The method of claim 1 , further comprising determining the expression level of at least nine genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
11. The method of claim 1 , further comprising determining the expression level of 10-20 genes selected from the group consisting of genes set forth in Tables 2 and 3 in said samples from said subject and said individuals not afflicted with PD.
12. The method of claim 1 , wherein expression level is determined by multiplex PCR of transcripts.
13. The method of claim 1 , wherein expression level is determined by northern blot.
14. The method of claim 1 , wherein expression level is determined by reverse transcription PCR (RT-PCR).
15. The method of claim 1 , wherein expression level is determined by microarray analysis of mRNA transcripts.
16. The method of claim 1 , wherein expression level is determined by RNAse protection.
17. The method of claim 1 , wherein expression level is determined by immunohistochemistry, ELISA or western blot.
18. The method of claim 15 , wherein microarray analysis comprises use of oligonucleotides that hybridize to mRNA transcripts or cDNAs for ST13, and wherein the oligonucleotides are disposed or directly synthesized on the surface of a chip or wafer.
19. The method of claim 18 , wherein said oligonucleotides are about 10 to about 50 nucleotides in length.